Meeting Banner
Abstract #1024

Diagnostic Performance of MRI for Assessing Tumor Response in Her-2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Aida Kuzucan1, Jeon-Hor Chen1,2, Rita S. Mehta3, Shadfar Bahri1, Philip M. Carpenter4, Hon J. Yu1, Orhan Nalcioglu1, Min-Ying L. Su1

1Center for Functional Onco-Imaging & Department of Radiological Science, University of California Irvine, Irvine, CA, United States; 2Department of Radiology, China Medical University Hospital, Taichung, Taiwan; 3Department of Medicine, University of California Irvine, CA, United States; 4Department of Pathology, University of California Irvine, CA, United States

In this study we evaluated the diagnostic performance of MRI for HER-2 negative breast cancer patients receiving neoadjuvant chemotherapy. The diagnostic performance between hormonal receptor (HR) positive and negative cancers was compared. Overall the pCR rate was higher in HR- than HR+ patients. The size discrepancy between MRI and pathologic diagnosis was higher in HR+ than HR- cancer, and also in low proliferating cancer with Ki-67 <40% than high proliferating cancers with Ki-67 > 40%. The results suggest that the diagnosis performance of MRI is better in tumors that are showing a good response than those showing a poor response.